Viridian Therapeutics reported a FY 2025 net loss of USD 342.6 million and a Q4 2025 net loss of USD 120.4 million. FY 2025 R&D expenses were USD 338.9 million and SG&A expenses were USD 95.3 million, while Q4 2025 R&D expenses were USD 89.2 million and SG&A expenses were USD 33.7 million. Total revenue was USD 70.8 million in FY 2025 and USD 0.1 million in Q4 2025. Cash, cash equivalents and marketable securities totaled USD 874.7 million at December 31, 2025. Shares outstanding on an as-converted basis were 116,126,148 at December 31, 2025. On the business side, the FDA’s Priority Review of Viridian’s veligrotug BLA for thyroid eye disease (TED) is ongoing with a PDUFA target action date of June 30, 2026, and the company said it is continuing commercial preparations for a planned mid-2026 U.S. launch if approved; the company also submitted a marketing authorization application to the EMA in January 2026. Viridian said elegrobart (VRDN-003) REVEAL-1 topline data in active TED remain on track for Q1 2026, with REVEAL-2 topline data in chronic TED on track for Q2 2026. Viridian also said it anticipates an IND submission in Q4 2026 for its anti-TSHR antibody program, and noted VRDN-008’s IND was cleared in January 2026 with a Phase 1 trial initiated and data expected in 2H 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260226760846) on February 26, 2026, and is solely responsible for the information contained therein.
Comments